NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.11 +0.12 (+0.15%) GOLD FUTURES
2,336.80 +14.50 (+0.62%) DOW
39,280.92 +224.53 (+0.57%) Bitcoin GBP
49,467.76 -486.78 (-0.97%)
Repare Therapeutics Inc. (RPTX)
- Simply Wall St.
Repare Therapeutics First Quarter 2024 Earnings: Beats Expectations
Repare Therapeutics ( NASDAQ:RPTX ) First Quarter 2024 Results Key Financial Results Revenue: US$52.4m (up by US$46.7m...
- Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass. & MONTREAL, May 07, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
MONTREAL & LAUSANNE, Switzerland, April 30, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial investigating lun
